← Russell 3000 cross-section

SIGA SIGA TECHNOLOGIES INC

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$213m
Revenue TTM
$54m
Net income TTM
$-3m
Free cash flow
Composite score
Sector rank
#2841

Valuation

P / E
EV / EBITDA
EV / sales
1.8
FCF yield
Earnings yield vs 10-yr
-6.05pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-5.2%
EBITDA margin
-19.7%
ROE
-1.7%
ROIC
-23.4%
Revenue growth
-70.1%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

The Company was the counterparty to the contract under which these international sales were made. For international sales in the first and second quarters, Meridian Medical Technologies ("Meridian") was the counterparty to contracts under which the sales were made (see discussion and definition below regarding International Promotion Agreement). For international sales in the third and fourth quarters, the Company was the counterparty to the contracts under which the sales were made. …SIGA TECHNOLOGIES INC, 10-K, period ended 2025-12-31, filed 2026-03-10

Read the full passage →